8th Annual Wolfe Research Healthcare Conference
Logotype for CVS Health Corporation

CVS Health (CVS) 8th Annual Wolfe Research Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for CVS Health Corporation

8th Annual Wolfe Research Healthcare Conference summary

9 Nov, 2026

Separation rationale

  • Annual portfolio reviews weigh evolving market, regulatory, competitor and customer dynamics; management sees each business positioned to compete independently and pursue durable long-term growth.

  • Two years ago, priorities were Aetna margin recovery and retail investment; management now describes the businesses as operating from a position of strength.

  • Management said expected ongoing dis-synergies are closer to the analyst’s ~$500 million estimate than figures above $1 billion; one-time separation costs will also be incurred.

  • Both standalone businesses are expected to have solid investment-grade balance sheets; management expects each to grow faster alone than together.

Pharmacy outlook

  • Retail pharmacy moved from a -5% trajectory three to four years ago to flat at Analyst Day and low-single-digit growth guidance at the earnings call; 2027 is expected to be its third consecutive year of AOI growth.

  • All pharmacy scripts have moved to a cost-based model after two years of client transitions; management expects reimbursement pressure to stabilize for the most part beyond 2028.

  • Standalone growth priorities: stabilize reimbursement, grow scripts slightly above market and build adjacent services; further detail is expected over the course of 2027.

  • Red Oak generic sourcing and the 10+ year wholesaler relationship will continue; Caremark retains brand cost-of-goods capabilities, while CVS Pharmacy remains a major generic purchaser.

  • Growth opportunities include DTC offerings, weight-loss solutions and scalable clinical and healthcare services across 9,000 local touchpoints.

Remaining healthcare businesses

  • Medicare Advantage is entering a third year of recovery; management expects continued growth and a return to appropriate margins, while prioritizing margin over growth through the 2028 recovery target.

  • Management characterized 2027 as a trough year for PBM pressures, with rebate-guarantee mitigation and 340B effects expected to work through by then; it expects a return to its previously indicated growth rate afterward.

  • Oak Street recovery has advanced, with management expecting positive contributions; PBM pricing is transitioning to a new model in response to FTC, CAA and Department of Labor developments.

  • The $35 billion deployable-capital figure remains the framework, split between the businesses; planned uses include dividends, share repurchases and appropriate M&A, while maintaining investment-grade positions.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from CVS Health